Sutro Biopharma, Inc. (NASDAQ:STRO – Get Free Report)’s stock price fell 10.1% on Monday . The stock traded as low as $35.48 and last traded at $35.05. 118,800 shares traded hands during trading, a decline of 36% from the average session volume of 185,397 shares. The stock had previously closed at $38.97.
More Sutro Biopharma News
Here are the key news stories impacting Sutro Biopharma this week:
- Positive Sentiment: HC Wainwright reiterated a Buy rating and $50 price target, and raised several near- and medium-term EPS estimates, including Q2 2026, Q3 2026, Q4 2026, FY2026, FY2027, FY2028, FY2029 and FY2030. STRO stock page
- Positive Sentiment: Lifesci Capital kept a Strong-Buy rating on STRO, signaling continued confidence in the company’s long-term outlook despite recent estimate revisions. STRO stock page
- Neutral Sentiment: HC Wainwright raised Q2 2026 EPS to $(2.33) from $(2.58), a modest improvement in the near-term outlook. STRO stock page
- Neutral Sentiment: HC Wainwright also increased its FY2026 EPS estimate to $(9.30) from $(10.32), and lifted FY2027 and FY2028 estimates, which suggests somewhat better profitability expectations over time. STRO stock page
- Negative Sentiment: Lifesci Capital cut multiple forward EPS estimates, including Q2 2026, Q3 2026, Q4 2026, FY2026, FY2027, FY2028, and FY2027 Q1/Q2/Q3/Q4, reinforcing expectations that Sutro Biopharma will remain deeply unprofitable in the near term. STRO stock page
- Negative Sentiment: Despite the bullish ratings, the broader takeaway is that analysts still expect substantial losses for Sutro Biopharma, which likely weighed on the stock. STRO stock page
Analyst Ratings Changes
Several analysts have commented on STRO shares. Wall Street Zen upgraded shares of Sutro Biopharma from a “sell” rating to a “hold” rating in a research note on Saturday, March 28th. Weiss Ratings restated a “sell (d-)” rating on shares of Sutro Biopharma in a research note on Friday, May 8th. HC Wainwright lifted their price objective on shares of Sutro Biopharma from $28.00 to $50.00 and gave the company a “buy” rating in a research note on Friday, May 15th. Leerink Partners set a $43.00 price objective on shares of Sutro Biopharma and gave the company an “outperform” rating in a research note on Friday, May 15th. Finally, Deutsche Bank Aktiengesellschaft lifted their price objective on shares of Sutro Biopharma from $51.00 to $55.00 and gave the company a “buy” rating in a research note on Wednesday, March 25th. Three equities research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Sutro Biopharma currently has a consensus rating of “Buy” and a consensus target price of $48.25.
Sutro Biopharma Price Performance
The stock’s fifty day moving average is $29.56 and its 200-day moving average is $18.65. The stock has a market capitalization of $513.45 million, a PE ratio of -2.81 and a beta of 1.63.
Sutro Biopharma (NASDAQ:STRO – Get Free Report) last announced its quarterly earnings results on Thursday, May 14th. The company reported ($2.94) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.74) by ($0.20). The company had revenue of $14.52 million for the quarter, compared to analysts’ expectations of $8.89 million. On average, analysts forecast that Sutro Biopharma, Inc. will post -9.48 EPS for the current year.
Institutional Trading of Sutro Biopharma
A number of hedge funds have recently added to or reduced their stakes in STRO. Invesco Ltd. boosted its holdings in Sutro Biopharma by 137.8% during the first quarter. Invesco Ltd. now owns 92,139 shares of the company’s stock worth $60,000 after buying an additional 53,390 shares in the last quarter. AQR Capital Management LLC boosted its holdings in Sutro Biopharma by 1,052.8% during the first quarter. AQR Capital Management LLC now owns 1,320,917 shares of the company’s stock worth $859,000 after buying an additional 1,206,330 shares in the last quarter. Strs Ohio purchased a new position in Sutro Biopharma during the first quarter valued at $99,000. Marshall Wace LLP purchased a new position in Sutro Biopharma during the second quarter valued at $166,000. Finally, Cerity Partners LLC lifted its holdings in Sutro Biopharma by 169.9% during the second quarter. Cerity Partners LLC now owns 105,437 shares of the company’s stock valued at $75,000 after purchasing an additional 66,372 shares in the last quarter. 96.99% of the stock is owned by hedge funds and other institutional investors.
About Sutro Biopharma
Sutro Biopharma, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel biologic drug candidates in the fields of oncology and immunology. The company leverages a proprietary cell-free protein synthesis platform, XpressCF™, to design and produce complex, multi-specific proteins that include antibody-drug conjugates, bispecific antibodies, and cytokine fusion proteins. This platform enables rapid generation and optimization of protein therapeutics that may not be feasible with traditional cell-based expression systems.
Founded in 2003 and headquartered in South San Francisco, California, Sutro Biopharma has built a pipeline of immuno-oncology candidates in various stages of preclinical and clinical development.
Featured Stories
- Five stocks we like better than Sutro Biopharma
- From Zepbound to Foundayo: Lilly’s Latest Results Support Oral GLP-1 Outlook
- AI Consolidation Begins: Blackstone & Google Forge an AI Empire
- USA Rare Earth Posts Strong Q1 2026 as Massive Serra Vera Deal Looms
- 3 Space Infrastructure Stocks Gaining Momentum Ahead of the SpaceX IPO
Receive News & Ratings for Sutro Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sutro Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
